Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 24;24(1):251.
doi: 10.1186/s12931-023-02554-8.

Walking the path of treatable traits in interstitial lung diseases

Francesco Amati  1   2 , Paolo Spagnolo  3 , Christopher J Ryerson  4 , Justin M Oldham  5 , Andrea Gramegna  6   7 , Anna Stainer  1   2 , Marco Mantero  6   7 , Nicola Sverzellati  8 , Donato Lacedonia  9 , Luca Richeldi  10 , Francesco Blasi  6   7 , Stefano Aliberti  11   12
Affiliations

Walking the path of treatable traits in interstitial lung diseases

Francesco Amati et al. Respir Res. .

Abstract

Interstitial lung diseases (ILDs) are complex and heterogeneous diseases. The use of traditional diagnostic classification in ILD can lead to suboptimal management, which is worsened by not considering the molecular pathways, biological complexity, and disease phenotypes. The identification of specific "treatable traits" in ILDs, which are clinically relevant and modifiable disease characteristics, may improve patient's outcomes. Treatable traits in ILDs may be classified into four different domains (pulmonary, aetiological, comorbidities, and lifestyle), which will facilitate identification of related assessment tools, treatment options, and expected benefits. A multidisciplinary care team model is a potential way to implement a "treatable traits" strategy into clinical practice with the aim of improving patients' outcomes. Multidisciplinary models of care, international registries, and the use of artificial intelligence may facilitate the implementation of the "treatable traits" approach into clinical practice. Prospective studies are needed to test potential therapies for a variety of treatable traits to further advance care of patients with ILD.

Keywords: Artificial intelligence; Biomarkers; Endotype; Interstitial lung diseases; Personalized medicine; Phenotype; Treatable traits.

PubMed Disclaimer

Conflict of interest statement

F.A. reports personal fees and other from Boehringer Ingelheim, outside the submitted work. P.S. reports grants and personal fees from Roche, grants, personal fees and non-financial support from PPM Services, personal fees from Galapagos, personal fees from Chiesi, grants, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Santhera Pharmaceuticals, personal fees from Lupin Pharmaceuticals, personal fees from Novartis, personal fees from Pieris Pharmaceuticals, outside the submitted work; and Wife employee of Novartis. C.R. reports grants and personal fees from Boehringer Ingelheim, personal fees from Hoffmann-La Roche, outside the submitted work. J.O. reports grants from National Institutes of Health, grants from Boehringer Ingelheim, during the conduct of the study; personal fees from Boehringer Ingelheim, personal fees from Roche/Genentech, other from Novartis, other from Endeavor BioMedicines, other from Genenetch, personal fees from Lupin Pharmaceuticals, personal fees from Gatehouse Bio, outside the submitted work. A.G. is an editorial board member of Respiratory Research. A.S. reports other from Boehringer Ingelheim, other from Roche, outside the submitted work. M.M. reports personal fees and other from Boehringer Ingelheim, outside the submitted work. N.S. has nothing to disclose. D.L. reports personal fees from Roche, personal fees from Boehringer Ingelheim, outside the submitted work. L.R. reports personal fees from Biogen, grants and personal fees from Roche, personal fees from ImmuneWorks, grants and personal fees from Boehringer Ingelheim, personal fees from Celgene, personal fees from Nitto, personal fees from FibroGen, personal fees from Promedior, personal fees from Pliant Therapeutics, personal fees from Asahi Kasei, personal fees from Toray, personal fees from BMS, personal fees from RespiVant, personal fees from CSL Behring, outside the submitted work. F.B. reports grants and personal fees from Astrazeneca, personal fees from Chiesi, personal fees from Glaxosmithkline, personal fees from Grifols, personal fees from Guidotti, grants and personal fees from Insmed, grants and personal fees from Menarini, personal fees from Novartis, personal fees from om pharma, personal fees from Pfizer, personal fees from Sanofi, personal fees from vertex, personal fees from Viatris, personal fees from Zambon, outside the submitted work. F.B is an editorial board member of Respiratory Research. S.A. reports personal fees from Bayer Healthcare, personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Zambon, grants and personal fees from Chiesi, grants and personal fees from INSMED, personal fees from GlaxoSmithKline, personal fees from Menarini, personal fees from ZetaCube Srl, grants from Fisher & Paykel, outside the submitted work.

Figures

Fig. 1
Fig. 1
Milestones in history of ILD
Fig. 2
Fig. 2
SWOT analysis of the treatable trait strategy in ILD. SWOT is an acronym that identifies the four elements of the analysis: strengths (S), weakness (W), opportunities (O), and threats (T). A SWOT analysis allows to critically explore advantages and disadvantages resulting from internal and external factors
See this image and copyright information in PMC

References

    1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748. - PMC - PubMed
    1. Bryan CS. What is the Oslerian tradition? Ann Intern Med. 1994;120(8):682–687. doi: 10.7326/0003-4819-120-8-199404150-00010. - DOI - PubMed
    1. Vanfleteren LEGW, Kocks JWH, Stone IS, et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax. 2014;69:72–79. - PubMed
    1. Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385:1789–1798. - PMC - PubMed
    1. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol. 2007;3:124. - PMC - PubMed